162 related articles for article (PubMed ID: 25529338)
1. Targeted prodrug approaches for hormone refractory prostate cancer.
Aloysius H; Hu L
Med Res Rev; 2015 May; 35(3):554-85. PubMed ID: 25529338
[TBL] [Abstract][Full Text] [Related]
2. Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy.
Denmeade SR; Mhaka AM; Rosen DM; Brennen WN; Dalrymple S; Dach I; Olesen C; Gurel B; Demarzo AM; Wilding G; Carducci MA; Dionne CA; Møller JV; Nissen P; Christensen SB; Isaacs JT
Sci Transl Med; 2012 Jun; 4(140):140ra86. PubMed ID: 22745436
[TBL] [Abstract][Full Text] [Related]
3. Prodrugs for improving tumor targetability and efficiency.
Mahato R; Tai W; Cheng K
Adv Drug Deliv Rev; 2011 Jul; 63(8):659-70. PubMed ID: 21333700
[TBL] [Abstract][Full Text] [Related]
4. Tumour endoproteases: the cutting edge of cancer drug delivery?
Atkinson JM; Siller CS; Gill JH
Br J Pharmacol; 2008 Apr; 153(7):1344-52. PubMed ID: 18204490
[TBL] [Abstract][Full Text] [Related]
5. Bacteria in cancer therapy: a novel experimental strategy.
Patyar S; Joshi R; Byrav DS; Prakash A; Medhi B; Das BK
J Biomed Sci; 2010 Mar; 17(1):21. PubMed ID: 20331869
[TBL] [Abstract][Full Text] [Related]
6. Cathepsin B-Overexpressed Tumor Cell Activatable Albumin-Binding Doxorubicin Prodrug for Cancer-Targeted Therapy.
Cho H; Shim MK; Yang S; Song S; Moon Y; Kim J; Byun Y; Ahn CH; Kim K
Pharmaceutics; 2021 Dec; 14(1):. PubMed ID: 35056979
[TBL] [Abstract][Full Text] [Related]
7. Prodrugs for Gene-Directed Enzyme-Prodrug Therapy (Suicide Gene Therapy).
Denny WA
J Biomed Biotechnol; 2003; 2003(1):48-70. PubMed ID: 12686722
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and preliminary cytotoxicity study of a cephalosporin-CC-1065 analogue prodrug.
Wang Y; Yuan H; Wright SC; Wang H; Larrick JW
BMC Chem Biol; 2001; 1(1):4. PubMed ID: 11710971
[TBL] [Abstract][Full Text] [Related]
9. Ion Pairing Enables Targeted Prodrug Activation via Red Light Photocatalysis: A Proof-of-Concept Study with Anticancer Gold Complexes.
Xie Z; Cao B; Zhao J; Liu M; Lao Y; Luo H; Zhong Z; Xiong X; Wei W; Zou T
J Am Chem Soc; 2024 Mar; 146(12):8547-8556. PubMed ID: 38498689
[TBL] [Abstract][Full Text] [Related]
10. Innovative therapies for prostate cancer treatment.
Syed S; Tolcher A
Rev Urol; 2003; 5 Suppl 3(Suppl 3):S78-84. PubMed ID: 16985955
[TBL] [Abstract][Full Text] [Related]
11. Self-Triggered Apoptosis Enzyme Prodrug Therapy (STAEPT): Enhancing Targeted Therapies via Recurrent Bystander Killing Effect by Exploiting Caspase-Cleavable Linker.
Chung SW; Choi JU; Cho YS; Kim HR; Won TH; Dimitrion P; Jeon OC; Kim SW; Kim IS; Kim SY; Byun Y
Adv Sci (Weinh); 2018 Jul; 5(7):1800368. PubMed ID: 30027061
[TBL] [Abstract][Full Text] [Related]
12. Radiation-induced prodrug activation: extending combined modality therapy for some solid tumours.
Farrer NJ; Higgins GS; Kunkler IH
Br J Cancer; 2022 May; 126(9):1241-1243. PubMed ID: 35217798
[TBL] [Abstract][Full Text] [Related]
13. Molecular foundations for personalized therapy in prostate cancer.
Fisher KW; Montironi R; Lopez Beltran A; Moch H; Wang L; Scarpelli M; Williamson SR; Koch MO; Cheng L
Curr Drug Targets; 2015; 16(2):103-14. PubMed ID: 25547910
[TBL] [Abstract][Full Text] [Related]
14. [¹⁷⁷Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer.
Kratochwil C; Giesel FL; Eder M; Afshar-Oromieh A; Benešová M; Mier W; Kopka K; Haberkorn U
Eur J Nucl Med Mol Imaging; 2015 May; 42(6):987-8. PubMed ID: 25573634
[No Abstract] [Full Text] [Related]
15. Protease-activated pore-forming peptides for the treatment and imaging of prostate cancer.
LeBeau AM; Denmeade SR
Mol Cancer Ther; 2015 Mar; 14(3):659-68. PubMed ID: 25537662
[TBL] [Abstract][Full Text] [Related]
16. Tomato thymidine kinase-based suicide gene therapy for malignant glioma--an alternative for Herpes Simplex virus-1 thymidine kinase.
Stedt H; Samaranayake H; Kurkipuro J; Wirth G; Christiansen LS; Vuorio T; Määttä AM; Piškur J; Ylä-Herttuala S
Cancer Gene Ther; 2015 Apr; 22(3):130-7. PubMed ID: 25613481
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a ⁶⁴Cu‑labeled 1,4,7‑triazacyclononane, 1‑glutaric acid‑4,7 acetic acid (NODAGA)‑galactose‑bombesin analogue as a PET imaging probe in a gastrin‑releasing peptide receptor‑expressing prostate cancer xenograft model.
Kim MH; Park JA; Woo SK; Lee KC; An GI; Kim BS; Kim KI; Lee TS; Kim CW; Kim KM; Kang JH; Lee YJ
Int J Oncol; 2015 Mar; 46(3):1159-68. PubMed ID: 25586565
[TBL] [Abstract][Full Text] [Related]
18. Value of bimodal (18)F-choline-PET/MRI and trimodal (18)F-choline-PET/MRI/TRUS for the assessment of prostate cancer recurrence after radiation therapy and radical prostatectomy.
Paparo F; Piccardo A; Bacigalupo L; Romagnoli A; Piccazzo R; Monticone M; Cevasco L; Campodonico F; Conzi GM; Carmignani G; Rollandi GA
Abdom Imaging; 2015 Aug; 40(6):1772-87. PubMed ID: 25579170
[TBL] [Abstract][Full Text] [Related]
19. Is neoadjuvant androgen deprivation therapy beneficial in prostate cancer treated with definitive radiotherapy?
Eom KY; Ha SW; Lee E; Kwak C; Lee SE
Radiat Oncol J; 2014 Dec; 32(4):247-55. PubMed ID: 25568853
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
